Introduction {#S1}
============

Ticks and tick-borne diseases that affect the health of dogs are expanding in different regions of the world \[[@R5]\]. Changes in human behaviour (increased outdoor recreation and international travel with companion animals) and changes in landscape ecology with increased wildlife host abundance for ticks are among the factors contributing to the increased incidence of canine tick-borne diseases \[[@R2]\]. Worldwide, canine monocytic ehrlichiosis, babesiosis and granulocytic anaplasmosis are the most common tick-borne diseases of dogs \[[@R13], [@R17]\].

The capacity of ticks to transmit these protozoan or bacterial pathogens varies widely. For instance, the cosmopolitan tick, *Rhipicephalus sanguineus*, is vector of *Ehrlichia canis,* which is the cause of canine monocytic ehrlichiosis. Moreover, *R. sanguineus* transmits a broad range of other pathogens, including *Babesia vogeli*, *Babesia gibsoni*, *Hepatozoon canis*, *Rickettsia conorii*, *Rickettsia rickettsii* and probably also *Anaplasma platys*, the cause of thrombocytic anaplasmosis \[[@R5]\].

Effective acaricidal control of ticks is a necessity in many parts of the world. Acaricidal treatment that kills ticks reduces the number of ticks capable of transmitting tick-borne pathogens.

In addition, the effectiveness of an acaricide that acts sufficiently fast to prevent transmission of tick-borne pathogens carries an important added value that needs to be demonstrated empirically. Studies that have been conducted thus far suggest that topically applied acaricides can assist in the prevention of the transmission of specific tick-borne pathogens. For instance, the ability of imidacloprid/permethrin to prevent transmission of *Anaplasma phagocytophilum*, the cause of granulocytic anaplasmosis, from naturally infected *Ixodes scapularis* ticks to dogs was reported several years ago \[[@R3]\].

A relatively new area of research is the development of transmission-blocking models, wherein the ability of tick control compounds to prevent transmission of pathogens can be effectively measured under controlled laboratory conditions \[[@R14]\]. First models were established for the blocking of transmission of *Babesia canis* by infected *Dermacentor reticulatus* ticks \[[@R9], [@R14]\]. Recently, further developments in this area have been the creation of a tick exposure laboratory model, wherein transmission of *E. canis* by infected *R*. *sanguineus* ticks can be studied \[[@R10]\]. Since the mode of action of compounds differs, it is necessary to evaluate each product's ability to prevent transmission of pathogens. For example, some products may have an irritant and toxic effect, such as permethrin and other substances such as amitraz present an effect which includes both an expellant effect, along with acaricidal properties \[[@R4], [@R8]\].

Here, this model was used to evaluate the efficacy of the topical product Advantix^®^, which combines imidacloprid 10% w/v with permethrin 50% w/v, in preventing the transmission of *E. canis* by infected *R. sanguineus* ticks to dogs.

Material and methods {#S2}
====================

Study design {#S3}
------------

This study was in compliance with the animal welfare requirements and carried out according to International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products Guideline 9: Good Clinical Practice \[[@R6]\]. It was a randomised, blinded efficacy study conducted with two groups of six dogs, which were males and females of mixed breed (mongrel), with a weight range of 13.8--18.8 kg. All dogs were kept individually in tick-proof kennels and were observed twice daily for health abnormalities. The dogs, all negative for *E. canis* specific antibodies in the indirect fluorescent antibody test (IFA), were ranked according to weight and divided randomly into two equal groups. Group 1 dogs were designated control and Group 2 dogs were treated with 10% w/v imidacloprid and 50% w/v permethrin on Day 0. The product was administered according to label instructions (topical spot-on at four spots along the back from the shoulder to the base of the tail) to each of the dogs in the acaricidal treatment group.

Infection of *R. sanguineus* ticks with *E. canis* {#S4}
--------------------------------------------------

*Rhipicephalus sanguineus* ticks, originating from France and maintained for several generations on rabbits under laboratory conditions, were used as a source to generate a batch of ticks infected by *E. canis*. *Rhipicephalus sanguineus* nymphs were fed on a susceptible laboratory-bred Beagle dog, previously inoculated with blood derived from a local case of canine monocytic ehrlichiosis, identified in Bloemfontein, South Africa. After moulting, the adult ticks were used as a basis for the study. A sample taken from the challenge batch of ticks was tested for *E. canis* by PCR and confirmed to be infected at a rate of 17%. The identity of this novel strain of *E. canis* was confirmed by its partial gene sequence (GenBank Accession No. [KC935387](http://KC935387)) of *E. canis* gp36 with a number of other *E. canis* isolates. It was found that *E. canis* (Bloemfontein) is closely related and formed a clade with several Asian isolates \[[@R11]\].

Tick infestation of dogs {#S5}
------------------------

On Days +7, +14, +21 and +28, fifty adult ticks were released into the individual tick-proof kennel of each dog to simulate natural exposure to ticks, instead of applying the ticks directly onto the dogs. The *E. canis*-infected ticks, which were used in the study, were unfed, at least one week old and had a balanced sex ratio of 50% male and 50% female ticks.

Monitoring of dogs {#S6}
------------------

The study animals were observed on a daily basis between Day −7 and Day +56 for general health purposes. The dogs were observed on an approximately hourly basis for 4 h after initiation of the acaricidal treatment to detect any adverse events. Full clinical examinations were conducted on Days −7, +21, +28, +35 +42, +49 and +56. Rectal body temperatures were recorded daily from Day +17 to Day +56. Additional clinical examinations were conducted on all dogs displaying an abnormally high body temperature (\>39.4 °C). Clinical examinations included general appearance, heart rate, respiration rate and body temperature. The examinations focussed on possible clinical manifestations of monocytic ehrlichiosis, which include fever, depression, anorexia, weight loss, haemorrhages and epistaxis. To prevent fatal ehrlichiosis, dogs with abnormally high body temperatures (\>39.4 °C) for at least two consecutive days and an abnormally low platelet count were treated with 10 mg/kg doxycycline *per os* for 21 consecutive days.

Blood samples for serology were collected on Days −7, +7, +21, +28, +35, +42, +49 and Day +56 from all dogs. Blood samples for platelet counts and PCR were only collected post tick challenge on Days +21, +28, +35, +42, +49 and Day +56 from all dogs. In dogs with suspected ehrlichiosis (e.g., due to low platelet count), additional samples were taken on the day of diagnosis, before rescue treatment. All samples collected were tested by PCR ([Table 4](#T4){ref-type="table"}).

Laboratory tests {#S7}
----------------

Blood samples in EDTA for platelet counts were examined by Pathcare Veterinary Laboratory, Bloemfontein, South Africa. Serum samples were frozen at −20 °C until assayed for *E. canis* antibodies using a commercial IFA test (IGG IFA, Fuller Laboratory, USA). The tests were performed according to the manufacturer's descriptions at the Department of Veterinary Tropical Diseases (DVTD), Faculty of Veterinary Science, University of Pretoria, South Africa.

A further blood sample collected in EDTA was centrifuged at 3,000 rpm for 15 min and the buffy coat stored in a −80 °C freezer, until PCR assayed. DNA extraction and PCR analysis of all buffy coat samples were performed in the molecular laboratory of ClinVet International Ltd. DNA extractions were performed using Qiagen DNeasy Blood and Tissue kit according to the instructions of the manufacturer. A novel primer set for PCR was designed based on the disulphide oxidoreductase gene of *E. canis*, as previously described \[[@R10]\].

Tick counts {#S8}
-----------

*In situ* tick thumb counts were carried out on all dogs 48 h after each exposure (Day +9, +16 and +23), but on Day +30 all ticks were counted and removed. The counts were recorded into six categories specified by the "*Guidelines for the Testing and Evaluation of the Efficacy of Antiparasitic Substances for the Treatment and Prevention of Tick and Flea infestation in Dogs and Cats*" adopted on 7 November 2007 by the Committee for Veterinary Medicinal Product of the European Agency for the Evaluation of Medicinal Products (EMEA/CVMP/005/2000-Rev.2). These six categories were: 1 = live, free; 2 = live, attached, unengorged (no filling of the alloscutum); 3 = live, attached, engorged (obvious or conspicuous filling of the alloscutum); 4 = killed, free; 5 = killed, attached, unengorged; 6 = killed, attached and engorged. Ticks counted and removed on Day +30 were also categorised within gender (male/female) in addition to recording them according to categories 1--6. Furthermore, each animal kennel was inspected daily from Day +14 up to Day +30 for any engorged ticks.

Statistics {#S9}
----------

In order to determine the effectiveness of the acaricidal treatment, the total number of ticks assigned to counting category 1, 2, 3 and 6 was transformed to the natural logarithm of (count + 1) and then corrected by subtracting one (1) for the calculation of the geometric means. The categories used to calculate effectiveness were according to the recommendations made by the "*Guidelines for the Testing and Evaluation of the Efficacy of Antiparasitic Substances for the Treatment and Prevention of Tick and Flea infestation in Dogs and Cats*" adopted on 7 November 2007 by the Committee for Veterinary Medicinal Product of the European Agency for the Evaluation of Medicinal Products (EMEA/CVMP/005/2000-Rev.2). In the acaricide-treated group, percentage reduction in tick counts compared to the control group was calculated using the formula 100 × (1 − *T*/*C*), wherein *T* and *C* were the geometric means of the acaricide-treated and control group, respectively. Effectiveness was also calculated based on the arithmetic group means. Furthermore, the groups were compared by an ANOVA with a treatment effect after a logarithmic transformation on the (count + 1) tick data.

Dogs which displayed *E. canis* antibodies and were also positive for *E. canis* DNA by PCR analysis were regarded as infected. The proportions of dogs infected in each group were compared by using Fisher's Exact Test. In addition, the exact 95% confidence interval for the blocking effect in Group 2 was calculated. Version 8 of SAS (Release 8.02 TS Level 02M0) was used for all statistical analyses, whereby the level of significance of the tests was set at 5%.

Results {#S10}
=======

Tick counts {#S11}
-----------

Both arithmetic and geometric mean tick counts recorded for the acaricidal treatment and control groups are provided in [Table 1](#T1){ref-type="table"}. Statistically significantly (*p* \< 0.05) less ticks were recorded on the treated dogs compared to the control dogs on all assessment days. Efficacy values (%) based on mean tick counts for the group treated once are summarised in [Table 1](#T1){ref-type="table"}. The acaricidal treatment was highly effective (between 96.1% and 98.9%, based on geometric means) against infestations with *R. sanguineus* ticks up to four week post acaricidal treatment.Table 1.Tick counts on dogs 48 h after environmental challenges by treatment group and percentage efficacies.Group 1 -- Control groupGroup 2 -- Advantix-treated groupLive ticksDead ticksLive ticksDead ticksDayFreeAtt; UeAtt; EFreeAtt; UeAtt; EFreeAtt; UeAtt; EFreeAtt; UeAtt; EEfficacy (%) based on arith. mean (geo. mean\#)+9\*0.0 (0.0)7.0 (6.7)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.5 (0.3)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)92.9 (96.1)+16\*0.0 (0.0)9.5 (8.0)2.8 (2.1)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.2 (0.1)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)98.6 (98.9)+23\*0.0 (0.0)10.3 (11.1)1.8 (1.6)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.3 (0.2)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)97.3 (98.3)+300.0 (0.0)18.5 (17.7)2.3 (2.1)0.0 (0.0)0.5 (0.3)0.8 (0.7)0.0 (0.0)0.5 (0.3)0.0 (0.0)0.0 (0.0)0.0 (0.0)0.0 (0.0)97.6 (98.3)\**In situ* counts. \#The geometric means of Group 2 differed statistically significantly (*p* \< 0.05) from those in Group 1 in all cases. Att = Attached; Ue = Unengorged; E = Engorged; Geo = geometric; Arith = Arithmetic.

*Ehrlichia canis* transmission blocking {#S12}
---------------------------------------

There were no adverse effects observed on the dogs with respect to the topical administration of the acaricidal treatment. Three dogs of the control group (CC5 CDA, E46 0EE and CC4 90E) with abnormally high body temperatures (\>39.4°C) received doxycycline at 10 mg/kg *per os* for 21 days starting on Day +23 (CC5 CDA), Day +31 (E46 0EE) and Day +38 (CC4 90E). Low platelet counts were observed in the same three dogs with elevated body temperature, but also in a fourth dog of the same group (9B4 937) ([Table 2](#T2){ref-type="table"}). Thrombocytopenia was evident in all four dogs; as a result of doxycycline treatment, values returned to normal between 200 and 500 × 10^9^/L towards the end of the study on Day +56 ([Table 2](#T2){ref-type="table"}). In all other animals platelet counts were within the normal range ([Table 2](#T2){ref-type="table"}).Table 2.Platelet counts in treated and control dogs.Platelet counts × 10^9^/LGroupDog no.Day 21Day 22Day 28Day 30Day 35Day 37Day 42Day 49Day 56ControlCC5 CDA11949--291----378339372CD2 B63370--469--343--386394340E46 0EE337--1835206--370382335CC4 90E240--284--1449719278256CC2 21F267--325--259--3101903349B4 937143--36167----601406508Treated groupE17 E19363--386--295--393395223DF5 A66338--363--219--344307430964 441364--411--307--388388451CC2 1BD319--391--264--357337353CC2 25E374--334--263--363321394CC4 55E262--311--234--321309298

The IFA test results are summarised in [Table 3](#T3){ref-type="table"}. All dogs included in the study tested negative for *E. canis* antibodies prior to the first tick infestation. Four control dogs (Group 1) developed specific antibodies against *E. canis* first detected on Day +21 (2 dogs), Day +28 (one dog) and Day +35 (one dog) and remained positive throughout to the end of the study ([Table 3](#T3){ref-type="table"}). The same control dogs that developed specific *E. canis* antibodies were confirmed PCR positive. None of the acaricide-treated dogs became seropositive neither PCR positive ([Table 4](#T4){ref-type="table"}).Table 3.*Ehrlichia canis* antibodies determined by IFA.GroupDog no.Day −7Day 7[1](#TFN1){ref-type="table-fn"}Day 21Day 28Day 35Day 42Day 49Day 56ControlCC5 CDA----[2](#TFN2){ref-type="table-fn"}POSPOSPOSPOSPOSPOSCD2 B63----------------E46 0EE------POSPOSPOSPOSPOSCC4 90E--------POSPOSPOSPOSCC2 21F----------------9B4 937----POSPOSPOSPOSPOSPOSTreated groupE17 E19----------------DF5 A66----------------964 441----------------CC2 1BD----------------CC2 25E----------------CC4 55E----------------[^1][^2] Table 4.Detection of *Ehrlichia canis* DNA by PCR in blood samples from individual dogs.PCRGroupDog no.Day 21Day 22Day 23Day 28Day 30Day 35Day 37Day 42Day 49Day 56ControlCC5 CDAPOSPOSPOSndndndndndndndCD2 B63--[2](#TFN4){ref-type="table-fn"}nd[1](#TFN3){ref-type="table-fn"}nd--nd--nd------E46 0EE--ndndPOSPOSndndndndndCC4 90E--ndnd--ndPOSPOSndndndCC2 21F--ndnd--nd--nd------9B4 937POSndndndndndndndndndTreated groupE17 E19--------------------DF5 A66--------------------964 441--------------------CC2 1BD--------------------CC2 25E--------------------CC4 55E--------------------[^3][^4]

In total, four out of six dogs became infected with *E. canis* in the control group and none in the acaricide-treated group (*p* = 0.0606).

Discussion {#S13}
==========

Advantix^®^ was highly effective (between 96.1% and 98.9%) against infestations of *R. sanguineus* ticks up to four week post acaricidal treatment ([Table 1](#T1){ref-type="table"}). Previous studies have demonstrated that the efficacy of the 10% w/v imidacloprid/50% w/v permethrin combination at 48 h is above 90%, dependent upon the tick species tested. The acaricidal efficacy of imidacloprid/permethrin spot-on against *R. sanguineus* has been reported to range between 91.5% and 97.6% for up to 37 days \[[@R7]\].

The first study which indicated that the combined action of 10% w/v imidacloprid/50% w/v permethrin could reduce pathogen transmission was published almost a decade ago (3), and reported the prevention of transmission of *A. phagocytophilum* from field-collected *I. scapularis* ticks to dogs treated with Advantix^®^. Another study conducted in southern Italy indicated that the application of 10% w/v imidacloprid/50% w/v permethrin as a topical spot-on reduced *E. canis* infection in dogs \[[@R15]\]. In another study using the same model a fipronil, amitraz and (S)-methoprene combination successfully prevented transmission of *E. canis* by *R. sanguineus* to dogs \[[@R10]\].

Although there was no statistical difference observed between the number of infected dogs in the two study groups, the fact that no infection was observed in Advantix^®^ treated dogs clearly demonstrated that a single administration of Advantix^®^ was able to prevent transmission of *E. canis* by *R. sanguineus* ticks for a duration of 4 weeks. The model that was employed did simulate natural exposure to ticks by releasing them into each individual dog kennel rather than applying them directly onto each dog.

Four out of six control dogs became infected with *E. canis,* as demonstrated by thrombocytopenia, development of specific *E. canis* antibodies and the presence of ehrlichial DNA in blood samples. A possible reason why two out of six control dogs did not develop monocytic ehrlichiosis may have been due to an insufficient number of ehrlichial organisms carried by those ticks that actually fed on these animals, or not all ticks being infected. Although one has to aim for an experimentally infected batch of ticks capable of infecting all control animals, the challenge has to be realistic and comparable with infection rates in field-collected ticks. In this study, 17% of ticks from the batch used to challenge the dogs was infected with *E. canis* as determined by PCR. This infection rate was regarded as comparable and representative for field situations. Although few such studies have been conducted, in general, infection rates with *E. canis* in field ticks are low. For instance, *E. canis* in ticks reported from different endemic areas (either mammalian hosts or questing adults in the environment) varied between 0.09% and 10% \[[@R1], [@R12], [@R16]\].

Unfortunately, the presence of *E. canis* by PCR in ticks found on the dogs at the end of the study was not determined. Such data would have provided additional evidence that the dogs had been in contact with infected ticks. Nevertheless, the fact remains that the majority of dogs in the control group (four of six) became infected with *E. canis*, but none of the treated dogs. Since all dogs were challenged with ticks from the same pool of infected ticks, it is very likely that the treated dogs encountered infected ticks as well. None of the six treated dogs became infected with *E. canis,* as confirmed by normal platelet values, lack of specific antibodies and PCR negativity. The results were consistent since the same 4 dogs were thrombocytopenic, seropositive as well as PCR positive ([Tables 2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}).

The transmission blocking capacity of Advantix^®^ was complete and provided full protection against monocytic canine ehrlichiosis for 4 weeks post acaricidal treatment.
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[^1]: Prior to tick challenge

[^2]: negative; POS = positive.

[^3]: nd = Not done

[^4]: negative; POS = positive.
